Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be
A global pandemic that's bringing the world to its knees. A big biotech with the first drug to demonstrate clinical efficacy in treating the viral disease. Healthcare experts stating that this drug would likely become the standard of care. Put all of that together and you'd think that the biotech in question would be on the verge of making an enormous amount of money from its antiviral drug.
This scenario is referring to Gilead Sciences (NASDAQ: GILD) and its drug remdesivir. But the last part of the scenario isn't a foregone conclusion. Here are three reasons Gilead's remdesivir might not be the mega-moneymaker that some think it will be.
Image source: Getty Images.
Source Fool.com
